*Result*: Large variations in total and allele-specific transcript expression in a disease mutation-independent manner.

Large variations in total and allele-specific transcript expression in a disease mutation-independent manner.

Freyberg M; Institute of Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany., Bewig M; Faculty of Medicine, Saarland University, Homburg, Germany., Bampi GB; Institute of Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany., Manfredi C; Department of Pediatrics, School of Medicine, Emory University, Atlanta, USA.; Children's Healthcare of Atlanta, Atlanta, USA., Joshi D; Department of Pediatrics, School of Medicine, Emory University, Atlanta, USA.; Children's Healthcare of Atlanta, Atlanta, USA., Rauscher R; Institute of Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany., Hong JS; Department of Pediatrics, School of Medicine, Emory University, Atlanta, USA.; Children's Healthcare of Atlanta, Atlanta, USA., Große-Onnebrink J; Münster University Hospital, Münster, Germany., Sutharsan S; Department of Pulmonary Medicine, Division of Cystic Fibrosis, University Medicine Essen-Ruhrlandklinik, University of Duisburg-Essen, Essen, Germany., Stehling F; Pediatric Pulmonology University Hospital of Essen, Essen, Germany., Bobis I; Christiane Herzog Zentrum Nord, Städtisches Krankenhaus Kiel, Kiel, Germany., Ballmann M; Pediatric and Adolescence Clinic, University Medicine Rostock, Rostock, Germany. Manfred.Ballmann@med.uni-rostock.de., Sorscher EJ; Department of Pediatrics, School of Medicine, Emory University, Atlanta, USA. esorscher@emory.edu.; Children's Healthcare of Atlanta, Atlanta, USA. esorscher@emory.edu., Ignatova Z; Institute of Biochemistry and Molecular Biology, University of Hamburg, Hamburg, Germany. zoya.ignatova@uni-hamburg.de.

Scientific reports [Sci Rep] 2026 Feb 27; Vol. 16 (1). Date of Electronic Publication: 2026 Feb 27.

Journal Article

English

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE; In Process

Original Publication: London : Nature Publishing Group, copyright 2011-

Lehner, B. Genotype to phenotype: Lessons from model organisms for human genetics. Nat. Rev. Genet. 14, 168–178. https://doi.org/10.1038/nrg3404 (2013). (PMID: 10.1038/nrg340423358379)
Lobo, I. Same genetic Mutation, different genetic disease phenotype. Nat. Educ. 1 (2008).
Cutting, G. R. Cystic fibrosis genetics: From molecular Understanding to clinical application. Nat. Rev. Genet. 16, 45–56 (2015). (PMID: 10.1038/nrg384925404111)
O’Neal, W. K. & Knowles, M. R. Cystic fibrosis disease modifiers: complex genetics defines the phenotypic diversity in a Monogenic disease. Annu. Rev. Genom. Hum. Genet. 19, 201–222. https://doi.org/10.1146/annurev-genom-083117-021329 (2018). (PMID: 10.1146/annurev-genom-083117-02132929709203)
Albitar, M. et al. Higher stability of mutant mRNA as compared to Wild-Type mRNA in diffuse large B-Cell lymphoma. Blood 134 https://doi.org/10.1182/blood-2019-128516 (2019).
Farinha, C. M. & Callebaut, I. Molecular mechanisms of cystic fibrosis - How mutations lead to misfunction and guide therapy. Biosci. Rep. 42 https://doi.org/10.1042/BSR20212006 (2022).
Hamasaki-Katagiri, N. et al. The importance of mRNA structure in determining the pathogenicity of synonymous and non-synonymous mutations in haemophilia. Haemophilia 23, e8–e17. https://doi.org/10.1111/hae.13107 (2017). (PMID: 10.1111/hae.1310727933712)
Kirchner, S. et al. Alteration of protein function by a silent polymorphism linked to tRNA abundance. PLoS Biol. 15, e2000779. https://doi.org/10.1371/journal.pbio.2000779 (2017). (PMID: 10.1371/journal.pbio.2000779285105925433685)
Oliver, K. E. et al. Slowing ribosome velocity restores folding and function of mutant CFTR. J. Clin. Invest. 129, 5236–5253. https://doi.org/10.1172/JCI124282 (2019). (PMID: 10.1172/JCI124282316577886877332)
Rauscher, R. et al. Positive epistasis between disease-causing missense mutations and silent polymorphism with effect on mRNA translation velocity. Proc. Natl. Acad. Sci. USA 118 https://doi.org/10.1073/pnas.2010612118 (2021).
Roos, D. & de Boer, M. Mutations in Cis that affect mRNA synthesis, processing and translation. Biochim. Biophys. Acta Mol. Basis Dis. 1867, 166166. https://doi.org/10.1016/j.bbadis.2021.166166 (2021). (PMID: 10.1016/j.bbadis.2021.16616633971252)
Shu, H. et al. FMRP links optimal codons to mRNA stability in neurons. Proc. Natl. Acad. Sci. USA. 117, 30400–30411. https://doi.org/10.1073/pnas.2009161117 (2020). (PMID: 10.1073/pnas.2009161117331996497720238)
van Willigen, M. et al. Folding-function relationship of the most common cystic fibrosis-causing CFTR conductance mutants. Life Sci. Alliance. 2 https://doi.org/10.26508/lsa.201800172 (2019).
Lazrak, A. et al. The silent codon change I507-ATC->ATT contributes to the severity of the DeltaF508 CFTR channel dysfunction. FASEB J. 27, 4630–4645. https://doi.org/10.1096/fj.13-227330 (2013). (PMID: 10.1096/fj.13-227330239074364046180)
Tan, K., Stupack, D. G. & Wilkinson, M. F. Nonsense-mediated RNA decay: an emerging modulator of malignancy. Nat. Rev. Cancer. 22, 437–451. https://doi.org/10.1038/s41568-022-00481-2 (2022). (PMID: 10.1038/s41568-022-00481-23562415211009036)
Clarke, L. A. et al. The effect of premature termination codon mutations on CFTR mRNA abundance in human nasal epithelium and intestinal organoids: a basis for read-through therapies in cystic fibrosis. Hum. Mut. 40, 326–334. https://doi.org/10.1002/humu.23692 (2019). (PMID: 10.1002/humu.2369230488522)
Masvidal, L. et al. Assessing the residual CFTR gene expression in human nasal epithelium cells bearing CFTR splicing mutations causing cystic fibrosis. Eur. J. Hum. Genet. 22, 784–791. https://doi.org/10.1038/ejhg.2013.238 (2014). (PMID: 10.1038/ejhg.2013.23824129438)
Domingo, J., Baeza-Centurion, P. & Lehner, B. The causes and consequences of genetic interactions (Epistasis). Annu. Rev. Genom. Hum. Genet. 20, 433–460. https://doi.org/10.1146/annurev-genom-083118-014857 (2019). (PMID: 10.1146/annurev-genom-083118-01485731082279)
Poelwijk, F. J., Krishna, V. & Ranganathan, R. The context-dependence of mutations: A linkage of formalisms. PLoS Comput. Biol. 12, e1004771. https://doi.org/10.1371/journal.pcbi.1004771 (2016). (PMID: 10.1371/journal.pcbi.1004771273376954919011)
Zhang, Z., Liu, F. & Chen, J. Conformational changes of CFTR upon phosphorylation and ATP binding. Cell 170, 483–491 e488. https://doi.org/10.1016/j.cell.2017.06.041 (2017).
Mekus, F. et al. Categories of deltaF508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics. Twin Res. 3, 277–293. https://doi.org/10.1375/136905200320565256 (2000). (PMID: 10.1375/13690520032056525611463149)
Hernandez-Amaris, M. F., Gomez-Vasquez, A. M. & Pachajua, H. H. Phenotypic variability of cystic fibrosis: case report of twins with F508/F508 mutation. Rev. Chil. Pediatr. 85, 470–475. https://doi.org/10.4067/S0370-41062014000400010 (2014). (PMID: 10.4067/S0370-4106201400040001025697321)
Ferec, C. & Cutting, G. R. Assessing the disease-liability of mutations in CFTR. Cold Spring Harb Perspect. Med. 2, a009480. https://doi.org/10.1101/cshperspect.a009480 (2012). (PMID: 10.1101/cshperspect.a009480232091793543074)
Ratjen, F. & Doring, G. Cystic fibrosis. Lancet 361, 681–689. https://doi.org/10.1016/S0140-6736(03)12567-6 (2003). (PMID: 10.1016/S0140-6736(03)12567-612606185)
Raraigh, K. S. et al. Complete CFTR gene sequencing in 5,058 individuals with cystic fibrosis informs variant-specific treatment. J. Cyst. Fibr. 21, 463–470. https://doi.org/10.1016/j.jcf.2021.10.011 (2022). (PMID: 10.1016/j.jcf.2021.10.011)
Bartoszewski, R. A. et al. A synonymous single nucleotide polymorphism in DeltaF508 CFTR alters the secondary structure of the mRNA and the expression of the mutant protein. J. Biol. Chem. 285, 28741–28748. https://doi.org/10.1074/jbc.M110.154575 (2010). (PMID: 10.1074/jbc.M110.154575206280522937902)
Kleizen, B., van Vlijmen, T., de Jonge, H. R. & Braakman, I. Folding of CFTR is predominantly cotranslational. Mol. Cell. 20, 277–287. https://doi.org/10.1016/j.molcel.2005.09.007 (2005). (PMID: 10.1016/j.molcel.2005.09.00716246729)
de Kok, J. B. et al. Normalization of gene expression measurements in tumor tissues: comparison of 13 endogenous control genes. Lab. Invest. 85, 154–159. https://doi.org/10.1038/labinvest.3700208 (2005). (PMID: 10.1038/labinvest.370020815543203)
Hsiao, L. L. et al. A compendium of gene expression in normal human tissues. Physiol. Genom. 7, 97–104. https://doi.org/10.1152/physiolgenomics.00040.2001 (2001). (PMID: 10.1152/physiolgenomics.00040.200111773596)
Vandesompele, J. et al. Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol. 3 (RESEARCH0034). https://doi.org/10.1186/gb-2002-3-7-research0034 (2002).
Masvidal, L. et al. GUSB and ATP2B4 are suitable reference genes for CFTR gene expression data normalization in nasal epithelium cells. J. Cyst. Fibr. 11, 398–404. https://doi.org/10.1016/j.jcf.2012.03.008 (2012). (PMID: 10.1016/j.jcf.2012.03.008)
Banks, C., Freeman, L., Cho, D. Y. & Woodworth, B. A. Acquired cystic fibrosis transmembrane conductance regulator dysfunction. World J. Otorhinolaryngol. Head Neck Surg. 4, 193–199. https://doi.org/10.1016/j.wjorl.2018.09.001 (2018). (PMID: 10.1016/j.wjorl.2018.09.001305060516251951)
Cho, D. Y. & Woodworth, B. A. Acquired cystic fibrosis transmembrane conductance regulator deficiency. Adv. Otorhinolaryngol. 79, 78–85. https://doi.org/10.1159/000445134 (2016). (PMID: 10.1159/00044513427466849)
Dransfield, M. T. et al. Acquired cystic fibrosis transmembrane conductance regulator dysfunction in the lower airways in COPD. Chest 144, 498–506. https://doi.org/10.1378/chest.13-0274 (2013). (PMID: 10.1378/chest.13-0274235387833734887)
Woodworth, B. A. Resveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia-Induced model of acquired CFTR deficiency. Laryngoscope 125 (Suppl 7), S1–S13. https://doi.org/10.1002/lary.25335 (2015). (PMID: 10.1002/lary.25335259461474579062)
Bienvenu, T. et al. Cystic fibrosis transmembrane conductance regulator channel dysfunction in non-cystic fibrosis bronchiectasis. Am. J. Respir Crit. Care Med. 181, 1078–1084. https://doi.org/10.1164/rccm.200909-1434OC (2010). (PMID: 10.1164/rccm.200909-1434OC20167849)
Bieth, E., Hamdi, S. M. & Mieusset, R. Genetics of the congenital absence of the Vas deferens. Hum. Genet. 140, 59–76. https://doi.org/10.1007/s00439-020-02122-w (2021). (PMID: 10.1007/s00439-020-02122-w32025909)
Casals, T. et al. Bronchiectasis in adult patients: An expression of heterozygosity for CFTR gene mutations? Clin. Genet. 65, 490–495. https://doi.org/10.1111/j.0009-9163.2004.00265.x (2004). (PMID: 10.1111/j.0009-9163.2004.00265.x15151509)
Cohn, J. A. et al. Increased risk of idiopathic chronic pancreatitis in cystic fibrosis carriers. Hum. Mut. 26, 303–307. https://doi.org/10.1002/humu.20232 (2005). (PMID: 10.1002/humu.2023216134171)
Miller, A. C. et al. Cystic fibrosis carriers are at increased risk for a wide range of cystic fibrosis-related conditions. Proc. Natl. Acad. Sci. USA. 117, 1621–1627. https://doi.org/10.1073/pnas.1914912117 (2020). (PMID: 10.1073/pnas.191491211731882447)
Pignatti, P. F., Bombieri, C., Marigo, C., Benetazzo, M. & Luisetti, M. Increased incidence of cystic fibrosis gene mutations in adults with disseminated bronchiectasis. Hum. Mol. Genet. 4, 635–639. https://doi.org/10.1093/hmg/4.4.635 (1995). (PMID: 10.1093/hmg/4.4.6357543317)
Raman, V., Clary, R., Siegrist, K. L., Zehnbauer, B. & Chatila, T. A. Increased prevalence of mutations in the cystic fibrosis transmembrane conductance regulator in children with chronic rhinosinusitis. Pediatrics 109, E13. https://doi.org/10.1542/peds.109.1.e13 (2002). (PMID: 10.1542/peds.109.1.e1311773581)
Swenson, C. E. et al. Treating non-cystic fibrosis bronchiectasis with CFTR modulators: Early case reports. Ann Case Report 9, (1910). https://doi.org/10.29011/2574-7754.101910 (2024).
Wang, X. & Cutting, G. R. Chronic rhinosinusitis. Adv. Otorhinolaryngol. 70, 114–121. https://doi.org/10.1159/000322487 (2011). (PMID: 10.1159/00032248721358193)
Wang, X., Kim, J., McWilliams, R. & Cutting, G. R. Increased prevalence of chronic rhinosinusitis in carriers of a cystic fibrosis mutation. Arch. Otolaryngol. Head Neck Surg. 131, 237–240. https://doi.org/10.1001/archotol.131.3.237 (2005). (PMID: 10.1001/archotol.131.3.23715781764)
Wang, X. et al. Mutation in the gene responsible for cystic fibrosis and predisposition to chronic rhinosinusitis in the general population. JAMA 284, 1814–1819. https://doi.org/10.1001/jama.284.14.1814 (2000). (PMID: 10.1001/jama.284.14.181411025834)
Nykamp, K. et al. Elucidating clinical phenotypic variability associated with the PolyT tract and TG repeats in CFTR. Hum. Mut. 42, 1165–1172. https://doi.org/10.1002/humu.24250 (2021). (PMID: 10.1002/humu.24250341960789292755)
Chu, C. S., Trapnell, B. C., Curristin, S., Cutting, G. R. & Crystal, R. G. Genetic basis of variable exon 9 skipping in cystic fibrosis transmembrane conductance regulator mRNA. Nat. Genet. 3, 151–156. https://doi.org/10.1038/ng0293-151 (1993). (PMID: 10.1038/ng0293-1517684646)
Groman, J. D. et al. Variation in a repeat sequence determines whether a common variant of the cystic fibrosis transmembrane conductance regulator gene is pathogenic or benign. Am. J. Hum. Genet. 74, 176–179. https://doi.org/10.1086/381001 (2004). (PMID: 10.1086/38100114685937)
Januszyk, M. et al. Evaluating the effect of cell culture on gene expression in primary tissue samples using microfluidic-based single cell transcriptional analysis. Microarrays (Basel). 4, 540–550. https://doi.org/10.3390/microarrays4040540 (2015). (PMID: 10.3390/microarrays4040540276002394996408)
Nilsson, L. M., Castresana-Aguirre, M., Scott, L. & Brismar, H. RNA-seq reveals altered gene expression levels in proximal tubular cell cultures compared to renal cortex but not during early glucotoxicity. Sci. Rep. 10, 10390. https://doi.org/10.1038/s41598-020-67361-3 (2020). (PMID: 10.1038/s41598-020-67361-3325873187316724)
Zaitseva, M., Vollenhoven, B. J. & Rogers, P. A. In vitro culture significantly alters gene expression profiles and reduces differences between myometrial and fibroid smooth muscle cells. Mol. Hum. Reprod. 12, 187–207. https://doi.org/10.1093/molehr/gal018 (2006). (PMID: 10.1093/molehr/gal01816524927)
Franzen, J. et al. DNA methylation changes during long-term in vitro cell culture are caused by epigenetic drift. Commun. Biol. 4, 598. https://doi.org/10.1038/s42003-021-02116-y (2021). (PMID: 10.1038/s42003-021-02116-y340119648134454)
Nestor, C. E. et al. Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems. Genome Biol. 16 https://doi.org/10.1186/s13059-014-0576-y (2015).
Keating, D. et al. VX-445-Tezacaftor-Ivacaftor in patients with cystic fibrosis and one or two Phe508del alleles. N Eng. J. Med. 379, 1612–1620. https://doi.org/10.1056/NEJMoa1807120 (2018). (PMID: 10.1056/NEJMoa1807120)
Taylor-Cousar, J. L. et al. Tezacaftor-Ivacaftor in patients with cystic fibrosis homozygous for Phe508del. N Eng. J. Med. 377, 2013–2023. https://doi.org/10.1056/NEJMoa1709846 (2017). (PMID: 10.1056/NEJMoa1709846)
Voelker, R. Patients with cystic fibrosis have new triple-drug combination. JAMA 322 (2068). https://doi.org/10.1001/jama.2019.19351 (2019).
Zemanick, E. T. et al. A phase 3 open-label study of elexacaftor/tezacaftor/ivacaftor in children 6 through 11 years of age with cystic fibrosis and at least one F508del allele. Am. J. Respir Crit. Care Med. 203, 1522–1532. https://doi.org/10.1164/rccm.202102-0509OC (2021). (PMID: 10.1164/rccm.202102-0509OC337340308483230)
Lundberg, E. et al. Defining the transcriptome and proteome in three functionally different human cell lines. Mol. Syst. Biol. 6, 450. https://doi.org/10.1038/msb.2010.106 (2010). (PMID: 10.1038/msb.2010.106211790223018165)
Vogel, C. & Marcotte, E. M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 13, 227–232. https://doi.org/10.1038/nrg3185 (2012). (PMID: 10.1038/nrg3185224114673654667)
Baker, E. K. et al. FMR1 mRNA from full mutation alleles is associated with ABC-C(FX) scores in males with fragile X syndrome. Sci. Rep. 10, 11701. https://doi.org/10.1038/s41598-020-68465-6 (2020). (PMID: 10.1038/s41598-020-68465-6326781527367290)
Kawarai, T. et al. Phenotype variability and allelic heterogeneity in KMT2B-Associated disease. Parkinsonism Relat. Disord. 52, 55–61. https://doi.org/10.1016/j.parkreldis.2018.03.022 (2018). (PMID: 10.1016/j.parkreldis.2018.03.02229653907)
Liu, Y., Beyer, A. & Aebersold, R. On the dependency of cellular protein levels on mRNA abundance. Cell 165, 535–550. https://doi.org/10.1016/j.cell.2016.03.014 (2016). (PMID: 10.1016/j.cell.2016.03.01427104977)
Estabrooks, S. & Brodsky, J. L. Regulation of CFTR biogenesis by the proteostatic network and pharmacological modulators. Int. J. Mol. Sci. 21 https://doi.org/10.3390/ijms21020452 (2020).
Kim, S. J. & Skach, W. R. Mechanisms of CFTR folding at the endoplasmic reticulum. Front. Pharmacol. 3, 201. https://doi.org/10.3389/fphar.2012.00201 (2012). (PMID: 10.3389/fphar.2012.00201232485973521238)
Corcoran, T. E., Broerman, M. J., Kliment, C. R. & Lo, C. CFTR expression decreases with age in several airway cell types. Sci. Rep. 14, 28832. https://doi.org/10.1038/s41598-024-80108-8 (2024). (PMID: 10.1038/s41598-024-80108-83957277211582707)
Erfinanda, L. et al. Loss of endothelial CFTR drives barrier failure and edema formation in lung infection and can be targeted by CFTR potentiation. Sci. Transl. Med. 14, eabg8577. https://doi.org/10.1126/scitranslmed.abg8577 (2022). (PMID: 10.1126/scitranslmed.abg857736475904)
Pinter, S. F. et al. Allelic imbalance is a prevalent and tissue-specific feature of the mouse transcriptome. Genetics 200, 537–549. https://doi.org/10.1534/genetics.115.176263 (2015). (PMID: 10.1534/genetics.115.176263258589124492378)
Wagner, J. R. et al. Computational analysis of whole-genome differential allelic expression data in human. PLoS Comput. Biol. 6, e1000849. https://doi.org/10.1371/journal.pcbi.1000849 (2010). (PMID: 10.1371/journal.pcbi.1000849206286162900287)
Wittkopp, P. J., Haerum, B. K. & Clark, A. G. Evolutionary changes in Cis and trans gene regulation. Nature 430, 85–88. https://doi.org/10.1038/nature02698 (2004). (PMID: 10.1038/nature0269815229602)
Borel, C. et al. Biased allelic expression in human primary fibroblast single cells. Am. J. Hum. Genet. 96, 70–80. https://doi.org/10.1016/j.ajhg.2014.12.001 (2015). (PMID: 10.1016/j.ajhg.2014.12.00125557783)
Despotes, K. A. & Donaldson, S. H. Current state of CFTR modulators for treatment of cystic fibrosis. Curr. Opin. Pharmacol. 65, 102239. https://doi.org/10.1016/j.coph.2022.102239 (2022). (PMID: 10.1016/j.coph.2022.10223935609385)
Raket, H. K. et al. Impact of elexacaftor/tezacaftor/ivacaftor on utilization of routine therapies in cystic fibrosis: Danish nationwide register study. J. Cyst. Fibr. https://doi.org/10.1016/j.jcf.2024.11.004 (2024). (PMID: 10.1016/j.jcf.2024.11.004)
Ridley, K. & Condren, M. Elexacaftor-Tezacaftor-Ivacaftor: The first triple-combination cystic fibrosis transmembrane conductance regulator modulating therapy. J. Pediatr. Pharmacol. Ther. 25, 192–197. https://doi.org/10.5863/1551-6776-25.3.192 (2020). (PMID: 10.5863/1551-6776-25.3.192322656027134581)
Muller-McNicoll, M., Rossbach, O., Hui, J. & Medenbach, J. Auto-regulatory feedback by RNA-binding proteins. J. Mol. Cell. Biol. 11, 930–939. https://doi.org/10.1093/jmcb/mjz043 (2019). (PMID: 10.1093/jmcb/mjz043311525826884704)
Hampton, T. H. et al. Gene expression responses of CF airway epithelial cells exposed to elexacaftor/tezacaftor/ivacaftor suggest benefits beyond improved CFTR channel function. Am. J. Physiol. 327, L905–L916. https://doi.org/10.1152/ajplung.00272.2024 (2024). (PMID: 10.1152/ajplung.00272.2024)
Schroeder, A. et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol. Biol. 7 https://doi.org/10.1186/1471-2199-7-3 (2006).

Keywords: Allele skewing; Cystic fibrosis; Gene expression; Monogenic diseases; mRNA

Date Created: 20260227 Latest Revision: 20260302

20260303

10.1038/s41598-026-40624-1

41760671

MEDLINE